476 results
6-K
EX-99.2
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
treatments for immune diseases
In addition to ITP, rilzabrutinib is being studied across a variety of immune-mediated diseases including asthma, chronic … patients with persistent or chronic immune thrombocytopenia (ITP). The safety profile of rilzabrutinib was consistent with that reported in previous
6-K
EX-99.1
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
, frexalimab has the potential to address both acute and chronic neuroinflammation in MS, without causing lymphocyte depletion. Sanofi is developing frexalimab
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
(AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis and prurigo nodularis. In Europe, Dupixent sales … myeloma) sales were €106 million, an increase of 28.7%, driven by strong growth in the US and the Rest of World.
Rezurock (chronic graft-versus-host
6-K
EX-99.1
SNY
Sanofi
20 Mar 24
New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
2:07pm
pivotal program. AD is a chronic, lifelong disease, which means we must strive to provide a portfolio of solutions to patients that matches … chronic inflammatory diseases, including asthma, hidradenitis suppurativa, scleroderma, celiac disease, and alopecia. In addition, we are exploring 6 other
6-K
EX-99.1
SNY
Sanofi
27 Feb 24
Current report (foreign)
11:35am
to address both acute and chronic neuroinflammation in MS without causing lymphocyte depletion. These data were previously presented at Consortium … upstream mechanism of action, frexalimab has the potential to address both acute and chronic neuroinflammation in MS, without causing lymphocyte
6-K
EX-99.4
9z34chvpm
27 Feb 24
Current report (foreign)
11:35am
6-K
1rhpxpdov 7vou
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.2
8hwrtroebt3wbt07u
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.5
nde9lc
27 Feb 24
Current report (foreign)
11:35am
6-K
EX-99.1
1tylvsqmz xjq03rp2e
15 Feb 24
Current report (foreign)
12:09pm
6-K
EX-99.1
4c6mdix 62z1
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
6-K
EX-99.1
jolpzsq8xd
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
6-K
EX-99.1
0b2g b97ln
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.1
cjvxktm4
1 Dec 23
Current report (foreign)
12:19pm
6-K
EX-99.1
w7d956tzcui8qexu9cx4
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
EX-99.2
lct8or9mo 1h51kgjx77
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
h6ksm
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
jiaa ngswpn
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
EX-99.1
c0p3682
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
EX-99.2
s3n3bdoy1 gafm39r1
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm